Ldlr-MS2 exosomes

Ldlr-MS2 exosomes are engineered extracellular vesicles designed for the targeted delivery of mRNA encoding the low-density lipoprotein receptor (Ldlr). The system utilizes a fusion of the MS2 bacteriophage coat protein (MCP) to an EV (exosome) membrane protein (e.g., CD9), along with insertion of customized MS2 stem-loop RNA aptamers into the Ldlr mRNA. This promotes selective encapsulation of Ldlr mRNA into the exosomes via MCP-MS2 stem-loop binding during exosome biogenesis in donor cells. Upon administration, a competitive "Ldlr releaser" (an RNA molecule with higher affinity for the MS2 aptamer) can be delivered to displace the Ldlr mRNA from MCP, allowing efficient release and translation of Ldlr mRNA in target cells, typically hepatocytes. The primary therapeutic aim is restoration of LDL receptor expression for the treatment of familial hypercholesterolemia and associated conditions in Ldlr-deficient models. This exosome-based, non-viral gene therapy platform addresses challenges of mRNA loading efficiency and release in exosome-mediated delivery systems.[1][3][5]

Other names

Ldlr-MS2 engineered exosomesLdlr-MS-2 engineered exosomesLdlr-MS 2 engineered exosomesLdlr mRNA-loaded exosomes via MS2 systemCD9-MCP exosomes containing Ldlr mRNACD-9-MCP exosomes containing Ldlr mRNACD 9-MCP exosomes containing Ldlr mRNA